RECRUITING

The CREST-2 Registry

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial (clinicaltrials.gov ID NCT02089217). Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with carotid artery stenting (CAS) performed by experienced and skilled interventionists. Interventionists' eligibility will be determined by a multi-specialty Interventional Management Committee (IMC). Patient eligibility will include patients with standard or high-risk, symptomatic or asymptomatic carotid artery disease. Patients will be followed for the occurrence of post-procedural complications. The primary safety and quality endpoint will be the occurrence of any stroke or death within the 30-day period following the stenting procedure. The safety and quality results from C2R will guide selection of interventionists for participation in the CREST-2 randomized clinical trial. Enrollment into C2R will begin in 2015 and continue until publication of the primary results of the randomized trial.

Official Title

The CREST-2 Registry

Quick Facts

Study Start:2015-02
Study Completion:2025-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02240862

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. 1. NYHA Class IV CHF
  2. 2. COPD on chronic continuous oxygen therapy
  3. 3. Severe (Class Childs D) liver failure
  4. 4. End-stage renal failure requiring dialysis
  5. 5. Cancer with metastatic spread and/or undergoing active chemotherapeutic treatment
  6. 6. Any dementia considered greater than "mild"

Contacts and Locations

Study Contact

Kimberlly A Castro-Roberts, MBA, CCRC
CONTACT
410-706-3941
knordstrom@som.umaryland.edu

Principal Investigator

Brajesh K Lal, MD
PRINCIPAL_INVESTIGATOR
University of Maryland

Study Locations (Sites)

University of Maryland - Administrative Center
Baltimore, Maryland, 21201
United States

Collaborators and Investigators

Sponsor: University of Maryland, Baltimore

  • Brajesh K Lal, MD, PRINCIPAL_INVESTIGATOR, University of Maryland

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2015-02
Study Completion Date2025-01

Study Record Updates

Study Start Date2015-02
Study Completion Date2025-01

Terms related to this study

Additional Relevant MeSH Terms

  • Carotid Artery Diseases